NUS researchers find drug that turns off ‘master switch’ in aggressive breast cancer
Researchers at the National University of Singapore have identified a drug capable of disabling a 'master switch' linked to aggressive breast cancer.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
NUS researchers identified a molecular switch driving metastasis and treatment resistance in triple-negative breast cancer. A drug targeting DP103 was found to turn off this master switch and showed promise for treating the aggressive cancer.
Epilogue added 83d ago, after coverage quieted.
The brief
Researchers from the National University of Singapore (NUS) have discovered a drug that targets a specific molecular mechanism described as a 'master switch' in aggressive forms of breast cancer. According to reporting from The Star and FemTech World, this drug is designed to turn off the biological switch that drives the progression of the disease. The discovery specifically focuses on triple-negative breast cancer (TNBC), which is characterized by its aggressiveness and resistance to conventional treatments. The Straits Times reports that the drug targets DP103, showing promise in managing this specific subtype of cancer. Multiple specialized outlets are emphasizing the molecular nature of this discovery.
Drug Target Review and Inside Precision Medicine highlight that the researchers have identified the molecular switch responsible for driving both metastasis and treatment resistance in triple-negative breast cancer. Medical Xpress frames the achievement as the identification of a molecule that drives one of the deadliest forms of breast cancer. The collective coverage from these six sources underscores a shift toward precision medicine by isolating a specific target, DP103, to combat the malignancy of the disease. Contextually, this research is significant because triple-negative breast cancer is noted for being particularly deadly and resistant to standard therapeutic options. By identifying a molecular switch, the NUS team has pinpointed the driver behind the cancer's ability to spread, or metastasize, to other parts of the body.
The ability to turn off this switch could potentially overcome the treatment resistance that often makes TNBC difficult for clinicians to manage, providing a new pathway for pharmacological intervention in aggressive cases. Future developments to monitor involve the continued testing and application of the drug targeting DP103. Based on the reports from The Straits Times and other outlets, the focus remains on whether this ability to disable the master switch can be consistently replicated to stop metastasis. Further details regarding the clinical transition of this drug or the specific stages of its current testing are not specified in the current coverage, but the identification of the molecule marks a foundational step in targeting treatment-resistant breast cancer.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 83d ago.
Quick answers
Which institution led this research?
The research was conducted by scientists at the National University of Singapore (NUS).
What specific target does the drug address?
The drug targets DP103, which is described as a molecular or 'master' switch in aggressive breast cancer.
What type of breast cancer is the focus of this study?
The research focuses on triple-negative breast cancer (TNBC), a form noted for its aggressiveness and treatment resistance.
Coverage (6)
- Drug turns off ‘master switch’ in aggressive breast cancer FemTech World · 86d ago
- NUS researchers identify molecular switch driving TNBC treatment resistance Drug Target Review · 86d ago
- Molecular Switch Driving Triple-Negative Breast Cancer Metastasis Identified Inside Precision Medicine · 86d ago
- Scientists identify molecule driving one of the deadliest forms of breast cancer Medical Xpress · 86d ago
- Drug targeting DP103 shows promise for triple negative breast cancer The Straits Times · 86d ago
- NUS researchers find drug that turns off ‘master switch’ in aggressive breast cancer The Star · 86d ago
Topics
Related trends
As Hormone Use Increases, Some Doctors Warn Slight Cancer Risk Is Being Overlooked
Doctors warn of slight cancer risk with hormone therapy for menopause
Drinking 2-3 Cups of Coffee Daily Linked to 43% Lower Risk of Liver Cancer
Multiple studies link 2-3 cups of coffee daily to a 43% lower risk of liver cancer, with benefits seen for both caffeinated and decaf coffee.
Why is colorectal cancer aggressive in younger patients? Boston researchers discover new clues
Boston researchers uncover new clues explaining why colorectal cancer behaves so aggressively in younger patients.
Doctor diagnosed with same type of breast cancer she researches
A physician who spent fifteen years studying breast cancer has received a personal diagnosis of the exact disease.
Newly discovered pathway fuels production of cancer-driving proteins
Stanford researchers have identified a protein translation pathway involving the METTL13 enzyme that drives cancer growth and drug resistance.
Rare and common genetic variants shape single-cell immune gene expression
New studies show rare and common DNA variants jointly steer immune cell activity, tightening the link between genetics and disease.